Instil Bio Q4 net loss per share narrows

Instil Bio

27/03/2026 11:09

Overview

U.S. biotechnology firm's Q4 net loss per share narrowed from prior year

Company ended 2025 with $76.3 mln in cash and marketable securities, expects runway beyond 2027

Instil discontinued AXN-2510 development, now pursuing acquisitions and in-licensing opportunities

Outlook

Instil expects cash position to fund current operating plan beyond 2027

Company is pursuing acquisitions and in-licensing opportunities for novel therapeutic candidates

Instil says there is no assurance any transaction will occur or on timing

Result Drivers

STRATEGIC SHIFT - Co discontinued AXN-2510 development and is now focusing on acquisitions and in-licensing opportunities to drive next phase of development

CAPITAL DEPLOYMENT - Co aims to leverage balance sheet for acquisitions and in-licensing, per CEO Bronson Crouch

Company press release: ID:nGNX89DbGf

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$8.19 mln
Q4 Basic EPS
-$1.21


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Instil Bio Inc is $27.00, about 223% above its March 26 closing price of $8.36

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)